AR078860A1 - Asociaciones farmaceuticas, composiciones farmaceuticas, medicamento y metodo para el tratamiento de animales - Google Patents
Asociaciones farmaceuticas, composiciones farmaceuticas, medicamento y metodo para el tratamiento de animalesInfo
- Publication number
- AR078860A1 AR078860A1 ARP100104031A ARP100104031A AR078860A1 AR 078860 A1 AR078860 A1 AR 078860A1 AR P100104031 A ARP100104031 A AR P100104031A AR P100104031 A ARP100104031 A AR P100104031A AR 078860 A1 AR078860 A1 AR 078860A1
- Authority
- AR
- Argentina
- Prior art keywords
- levamisole
- salts
- nitroxynil
- pharmaceutical
- pharmaceutical compositions
- Prior art date
Links
- 229940079593 drug Drugs 0.000 title abstract 4
- 239000003814 drug Substances 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- 241001465754 Metazoa Species 0.000 title abstract 3
- HLFSDGLLUJUHTE-SNVBAGLBSA-N Levamisole Chemical compound C1([C@H]2CN3CCSC3=N2)=CC=CC=C1 HLFSDGLLUJUHTE-SNVBAGLBSA-N 0.000 abstract 7
- 229960001614 levamisole Drugs 0.000 abstract 5
- 239000004480 active ingredient Substances 0.000 abstract 4
- 150000003839 salts Chemical class 0.000 abstract 4
- 230000000507 anthelmentic effect Effects 0.000 abstract 3
- SGKGVABHDAQAJO-UHFFFAOYSA-N nitroxynil Chemical compound OC1=C(I)C=C(C#N)C=C1[N+]([O-])=O SGKGVABHDAQAJO-UHFFFAOYSA-N 0.000 abstract 3
- -1 nitroxynil compound Chemical class 0.000 abstract 3
- 239000005660 Abamectin Substances 0.000 abstract 2
- UVGTXNPVQOQFQW-UHFFFAOYSA-N Disophenol Chemical compound OC1=C(I)C=C([N+]([O-])=O)C=C1I UVGTXNPVQOQFQW-UHFFFAOYSA-N 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 abstract 2
- 229960002669 albendazole Drugs 0.000 abstract 2
- HXHWSAZORRCQMX-UHFFFAOYSA-N albendazole Chemical compound CCCSC1=CC=C2NC(NC(=O)OC)=NC2=C1 HXHWSAZORRCQMX-UHFFFAOYSA-N 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- FXWHFKOXMBTCMP-WMEDONTMSA-N milbemycin Natural products COC1C2OCC3=C/C=C/C(C)CC(=CCC4CC(CC5(O4)OC(C)C(C)C(OC(=O)C(C)CC(C)C)C5O)OC(=O)C(C=C1C)C23O)C FXWHFKOXMBTCMP-WMEDONTMSA-N 0.000 abstract 2
- 229960004546 thiabendazole Drugs 0.000 abstract 2
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 abstract 2
- 239000004308 thiabendazole Substances 0.000 abstract 2
- 235000010296 thiabendazole Nutrition 0.000 abstract 2
- AZSNMRSAGSSBNP-UHFFFAOYSA-N 22,23-dihydroavermectin B1a Natural products C1CC(C)C(C(C)CC)OC21OC(CC=C(C)C(OC1OC(C)C(OC3OC(C)C(O)C(OC)C3)C(OC)C1)C(C)C=CC=C1C3(C(C(=O)O4)C=C(C)C(O)C3OC1)O)CC4C2 AZSNMRSAGSSBNP-UHFFFAOYSA-N 0.000 abstract 1
- IBSREHMXUMOFBB-JFUDTMANSA-N 5u8924t11h Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1=C[C@H](C)[C@@H]([C@@H](C)CC)O[C@]11O[C@H](C\C=C(C)\[C@@H](O[C@@H]2O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C2)[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 IBSREHMXUMOFBB-JFUDTMANSA-N 0.000 abstract 1
- SPBDXSGPUHCETR-JFUDTMANSA-N 8883yp2r6d Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O[C@@H]([C@@H](C)CC4)C(C)C)O3)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C.C1C[C@H](C)[C@@H]([C@@H](C)CC)O[C@@]21O[C@H](C\C=C(C)\[C@@H](O[C@@H]1O[C@@H](C)[C@H](O[C@@H]3O[C@@H](C)[C@H](O)[C@@H](OC)C3)[C@@H](OC)C1)[C@@H](C)\C=C\C=C/1[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\1)O)C[C@H]4C2 SPBDXSGPUHCETR-JFUDTMANSA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- RAOCRURYZCVHMG-UHFFFAOYSA-N N-(6-propoxy-1H-benzimidazol-2-yl)carbamic acid methyl ester Chemical compound CCCOC1=CC=C2N=C(NC(=O)OC)NC2=C1 RAOCRURYZCVHMG-UHFFFAOYSA-N 0.000 abstract 1
- 229910019142 PO4 Inorganic materials 0.000 abstract 1
- 229950008167 abamectin Drugs 0.000 abstract 1
- 239000002671 adjuvant Substances 0.000 abstract 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 abstract 1
- 150000001491 aromatic compounds Chemical class 0.000 abstract 1
- 150000001556 benzimidazoles Chemical class 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960003997 doramectin Drugs 0.000 abstract 1
- QLFZZSKTJWDQOS-YDBLARSUSA-N doramectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C3CCCCC3)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C/C=C/[C@@H]2C)/C)O[C@H]1C QLFZZSKTJWDQOS-YDBLARSUSA-N 0.000 abstract 1
- WPNHOHPRXXCPRA-TVXIRPTOSA-N eprinomectin Chemical compound O1[C@@H](C)[C@@H](NC(C)=O)[C@H](OC)C[C@@H]1O[C@H]1[C@@H](OC)C[C@H](O[C@@H]2C(=C/C[C@@H]3C[C@@H](C[C@@]4(O3)C=C[C@H](C)[C@@H](C(C)C)O4)OC(=O)[C@@H]3C=C(C)[C@@H](O)[C@H]4OC\C([C@@]34O)=C\C=C/[C@@H]2C)\C)O[C@H]1C WPNHOHPRXXCPRA-TVXIRPTOSA-N 0.000 abstract 1
- 229960002346 eprinomectin Drugs 0.000 abstract 1
- 229960005473 fenbendazole Drugs 0.000 abstract 1
- HDDSHPAODJUKPD-UHFFFAOYSA-N fenbendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1SC1=CC=CC=C1 HDDSHPAODJUKPD-UHFFFAOYSA-N 0.000 abstract 1
- 229960004500 flubendazole Drugs 0.000 abstract 1
- CPEUVMUXAHMANV-UHFFFAOYSA-N flubendazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=C(F)C=C1 CPEUVMUXAHMANV-UHFFFAOYSA-N 0.000 abstract 1
- 229960002418 ivermectin Drugs 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 229960003439 mebendazole Drugs 0.000 abstract 1
- OPXLLQIJSORQAM-UHFFFAOYSA-N mebendazole Chemical compound C=1C=C2NC(NC(=O)OC)=NC2=CC=1C(=O)C1=CC=CC=C1 OPXLLQIJSORQAM-UHFFFAOYSA-N 0.000 abstract 1
- ZLBGSRMUSVULIE-GSMJGMFJSA-N milbemycin A3 Chemical class O1[C@H](C)[C@@H](C)CC[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 ZLBGSRMUSVULIE-GSMJGMFJSA-N 0.000 abstract 1
- YZBLFMPOMVTDJY-CBYMMZEQSA-N moxidectin Chemical compound O1[C@H](C(\C)=C\C(C)C)[C@@H](C)C(=N/OC)\C[C@@]11O[C@H](C\C=C(C)\C[C@@H](C)\C=C\C=C/2[C@]3([C@H](C(=O)O4)C=C(C)[C@@H](O)[C@H]3OC\2)O)C[C@H]4C1 YZBLFMPOMVTDJY-CBYMMZEQSA-N 0.000 abstract 1
- 229960004816 moxidectin Drugs 0.000 abstract 1
- 229960002762 oxibendazole Drugs 0.000 abstract 1
- 150000002923 oximes Chemical class 0.000 abstract 1
- 244000045947 parasite Species 0.000 abstract 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 abstract 1
- 239000010452 phosphate Substances 0.000 abstract 1
- AFJYYKSVHJGXSN-KAJWKRCWSA-N selamectin Chemical compound O1[C@@H](C)[C@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C(/C)=C/C[C@@H](O[C@]2(O[C@@H]([C@@H](C)CC2)C2CCCCC2)C2)C[C@@H]2OC(=O)[C@@H]([C@]23O)C=C(C)C(=N\O)/[C@H]3OC\C2=C/C=C/[C@@H]1C AFJYYKSVHJGXSN-KAJWKRCWSA-N 0.000 abstract 1
- 229960002245 selamectin Drugs 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 150000003462 sulfoxides Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/05—Phenols
- A61K31/06—Phenols the aromatic ring being substituted by nitro groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/429—Thiazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Asociaciones farmacéuticas antihelmínticas que contienen compuestos aromáticos iodados, tales como disofenol o nitroxinilo, con otros ingredientes activos farmacéuticos que tienen por objetivo el tratamiento de animales. Más específicamente, composiciones farmacéuticas que contienen disofenol o nitroxinilo con por lo menos otro ingrediente activo antihelmíntico, seleccionado de entre benzimidazoles, tiabendazol, sales de levamisol o tetramisol, avermectinas o milbemicinas y, más preferentemente, sales de levamisol seleccionadas de entre cloruro o fosfato de levamisol. Asimismo, medicamentos y métodos de tratamiento de animales que comprenden esos medicamentos antihelmínticos. Reivindicacion 7: Composiciones farmacéuticas, caracterizadas porque contienen como ingredientes activos el compuesto disofenol en cantidades que varían de 0,5% a 50% en peso, o un compuesto nitroxinilo o sus sales aceptables en farmacia en cantidades que varían de 0,3% a 30% en peso, y un compuesto levamisol o sus sales aceptables en farmacia, en cantidades que varían de 0,3% a 30% en peso, además de agentes coadyuvantes aceptables en farmacia. Reivindicacion 17: Composiciones farmacéuticas de acuerdo con la reivindicacion 7, caracterizadas porque contienen concomitantemente disofenol y nitroxinilo combinados con cantidades farmacéuticamente eficaces para el control de parásitos de por lo menos un ingrediente activo seleccionado de entre sales de levamisol o tetramisol, tiabendazol mebendazol albendazol, sulfoxido de albendazol, flubendazol, oxifendazol, fenbendazol, oxibendazol, abamectina, ivermectina, doramectina, eprinomectina, selamectina, moxidectina, milbemicina y milbemicina oxima, preferentemente levamisol en la forma de sus sales preparadas con ácido clorhídrico o ácido fosforico, a más de agentes coadyuvantes aceptables en farmacia. Reivindicacion 23: Medicamento de acuerdo con cualquiera de las reivindicaciones 20 a 22, caracterizado por ser producido en forma solida o en forma líquida, mediante sus combinaciones con vehículos y otros componentes aceptables en farmacia.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| BRPI0904365-9A BRPI0904365A2 (pt) | 2009-11-05 | 2009-11-05 | associações farmacêuticas, composições farmacêuticas, medicamento e método para o tratamento de animais |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR078860A1 true AR078860A1 (es) | 2011-12-07 |
Family
ID=43969501
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104031A AR078860A1 (es) | 2009-11-05 | 2010-11-01 | Asociaciones farmaceuticas, composiciones farmaceuticas, medicamento y metodo para el tratamiento de animales |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20120277175A1 (es) |
| EP (1) | EP2497467A4 (es) |
| AR (1) | AR078860A1 (es) |
| AU (1) | AU2010314766A1 (es) |
| BR (1) | BRPI0904365A2 (es) |
| MX (1) | MX2012005229A (es) |
| UY (1) | UY33003A (es) |
| WO (1) | WO2011054068A1 (es) |
| ZA (1) | ZA201203281B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI2981269T3 (fi) | 2013-04-04 | 2023-09-27 | Boehringer Ingelheim Vetmedica Gmbh | Aineenvaihduntahäiriöiden hoito hevoseläimillä |
| BR102013031277B1 (pt) * | 2013-12-05 | 2018-10-02 | Ouro Fino Participacoes E Empreendimentos S A | processo para preparar uma suspensão anti-helmíntica e suspensão anti-helmíntica injetável |
| WO2015091313A1 (en) | 2013-12-17 | 2015-06-25 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of metabolic disorders in feline animals |
| CN115282284A (zh) | 2014-01-23 | 2022-11-04 | 勃林格殷格翰动物保健有限公司 | 犬科动物中代谢紊乱的治疗 |
| EP3721882B1 (en) | 2014-04-01 | 2024-08-28 | Boehringer Ingelheim Vetmedica GmbH | Treatment of pituitary pars intermedia dysfunction in equine animals |
| MX388192B (es) | 2014-09-25 | 2025-03-19 | Boehringer Ingelheim Vetmedica Gmbh | Tratamiento de combinación y/o prevención de trastornos metabólicos en animales equinos. |
| CA2996458C (en) * | 2015-08-27 | 2024-04-23 | Boehringer Ingelheim Vetmedica Gmbh | Liquid pharmaceutical compositions comprising sglt-2 inhibitors |
| WO2018167628A1 (en) | 2017-03-13 | 2018-09-20 | Ftf Pharma Private Limited | Pharmaceutical composition of oral suspension of immunosuppressive agents |
| EP3668508A1 (en) | 2017-08-19 | 2020-06-24 | FTF Pharma Private Limited | An oral pharmaceutical composition comprising zonisamide and process of preparation thereof |
| CN112566625A (zh) * | 2018-08-18 | 2021-03-26 | 夫特弗制药私人有限公司 | 口服剂量的化学治疗药物悬浮液 |
| GB2591396B (en) | 2018-08-18 | 2023-06-07 | Ftf Pharma Private Ltd | Pharmaceutical suspension for oral dosage |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU527154B2 (en) * | 1978-12-15 | 1983-02-17 | Pitman-Moore Australia Limited | Composition and process |
| NZ202422A (en) * | 1981-11-25 | 1985-02-28 | Ici Australia Ltd | D, l-and l-2,3,5,6-tetrahydro-6-phenylimidazo(2,1-b)thiazolium 4-cyano-2-iodo-6-nitrophenoxide and veterinary compositions |
| GB8331037D0 (en) * | 1983-11-21 | 1983-12-29 | May & Baker Ltd | Compositions of matter |
| KR890000906B1 (ko) * | 1986-06-28 | 1989-04-13 | 주식회사 한국미생물연구소 | 간질 및 소화관내 선충류 구충을 위한 니트록시닐과 레바미솔 복합주사제의 제조방법 |
| NZ267366A (en) * | 1993-06-15 | 1996-12-20 | Univ Australian | Controlling fasciola and other helminths using a synergistic composition of at least two anthelmintic active drugs each being selected from a different class of drug |
| DE60025198D1 (de) * | 1999-06-04 | 2006-02-02 | Nufarm Ltd | Stabile biozidale zusammensetzung |
| BRPI0505716B1 (pt) | 2005-12-15 | 2016-12-20 | Npa Núcleo De Pesquisas Aplic S Ltda | sal orgânico de levamisol, processo de preparação do mesmo, composição farmacêutica e seu uso no combate de helmintiases |
| BRPI0506279B1 (pt) * | 2005-12-16 | 2018-01-09 | Npa - Núcleo De Pesquisas Aplicadas Ltda | Composição sinergística de antihelmínticos e endectocidas |
| TW201111358A (en) * | 2009-06-18 | 2011-04-01 | Intervet Int Bv | Anthelmintic agents and their use |
-
2009
- 2009-11-05 BR BRPI0904365-9A patent/BRPI0904365A2/pt not_active Application Discontinuation
-
2010
- 2010-11-01 AR ARP100104031A patent/AR078860A1/es unknown
- 2010-11-04 UY UY0001033003A patent/UY33003A/es not_active Application Discontinuation
- 2010-11-05 MX MX2012005229A patent/MX2012005229A/es not_active Application Discontinuation
- 2010-11-05 AU AU2010314766A patent/AU2010314766A1/en not_active Abandoned
- 2010-11-05 US US13/505,341 patent/US20120277175A1/en not_active Abandoned
- 2010-11-05 EP EP10827738A patent/EP2497467A4/en not_active Withdrawn
- 2010-11-05 WO PCT/BR2010/000361 patent/WO2011054068A1/pt not_active Ceased
-
2012
- 2012-05-04 ZA ZA2012/03281A patent/ZA201203281B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20120277175A1 (en) | 2012-11-01 |
| UY33003A (es) | 2011-06-30 |
| EP2497467A1 (en) | 2012-09-12 |
| ZA201203281B (en) | 2013-06-26 |
| WO2011054068A1 (pt) | 2011-05-12 |
| MX2012005229A (es) | 2012-09-07 |
| AU2010314766A1 (en) | 2012-06-21 |
| BRPI0904365A2 (pt) | 2011-11-16 |
| EP2497467A4 (en) | 2013-03-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR078860A1 (es) | Asociaciones farmaceuticas, composiciones farmaceuticas, medicamento y metodo para el tratamiento de animales | |
| AR081754A1 (es) | Composiciones parasiticidas que comprenden multiples agentes activos, metodos y usos de las mismas | |
| RU2011138021A (ru) | Комбинация авермектина или милбемицина с адренергическими рецепторами для лечения или профилактики дерматологических заболеваний | |
| HRP20211042T1 (hr) | Dugodjelujuće injektibilne formulacije koje sadrže antiparazitske izoksazolinske spojeve i njihove uporabe | |
| JP5462456B2 (ja) | 駆虫配合剤 | |
| UY30373A1 (es) | Derivados de fenilalanina, procedimientos de preparacion y aplicaciones | |
| AR058679A1 (es) | Preparacion farmaceutica que contiene meloxicam | |
| CO6710926A2 (es) | Compuestos de n-heteroarilo | |
| CO2022014073A2 (es) | Compuestos antivirales y métodos para la administración de los mismos | |
| ECSP088102A (es) | Compuestos para el tratamiento de infecciones bacterianas resistentes a múltiples fármacos | |
| GT200800219A (es) | Derivados de purina para utilizarse como agonistas del receptor de adenosina a2a | |
| AR061771A1 (es) | Sistema de administracion terapeutica | |
| MX2018011278A (es) | Composiciones para la liberacion controlada de cisteamina y el tratamiento sistemico de trastornos sensibles a la cisteamina. | |
| CO6571900A2 (es) | Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos | |
| UY30094A1 (es) | Compuestos químicos | |
| AU2022252717B2 (en) | Stable veterinary anthelmintic formulations | |
| CO2018002394A2 (es) | Método para la inhibición de la absorción de lípidos y/o la promoción de excreción de lípidos usando d-psicosa | |
| GT200900062A (es) | Nuevos compuestos de diosmetina, un proceso para su preparacion y las composiciones farmaceuticas que los contienen | |
| BR112014013371A2 (pt) | formulações injetáveis de moxidectina de longa ação e novas formas de cristal de moxidectina | |
| US10052341B2 (en) | Method for preparing an anthelmintic composition, anthelmintic composition, veterinary treatment method and anthelmintic treatment method | |
| AR075428A1 (es) | Formulacion de doramectina en dosis elevada | |
| PE20151726A1 (es) | Formulaciones veterinarias estables de combinacion de lactonas macrociclicas e imidazotiazoles | |
| AR093275A1 (es) | Una composicion farmaceutica soluble en agua que comprende al menos una sustancia terapeuticamente activa de caracteristicas hidrofobicas y al menos un compuesto seleccionado entre los sialoglicoesfingolipidos, los glicoesfingolipidos o una mezcla de sialoglicoesfingolipidos y glicoesfingolipidos | |
| UY30699A1 (es) | Derivados sustituidos de 4-fenilamino-quinolina-3-carboxamidas, sales farmacéuticamente aceptables, procesos de preparacion, composiciones conteniéndolos y aplicaciones | |
| MX2008007773A (es) | Composicion veterinaria que comprende una sal organica de levamisol en combinacion con por lo menos una avermectina y/o milbemicina. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |